Healthcare Professionals Patients
ProAir HFA inhaler design makes the difference

ProAir® HFA delivers a warmer, lower-impact, longer-duration plume

The ProAir® HFA plume may be easier for patients to inhale.1-3 ProAir® HFA produces a longer-duration plume compared with some other albuterol HFA inhalers—almost 2.5 times as long as the Ventolin® HFA plume.3 The longer-duration plume may allow patients more time to inhale the medication.1-3 The longer-duration plume delivered by ProAir® HFA may be more forgiving for patients with poor inhaler technique.1,3,4

To learn more about the ProAir® HFA plume, watch our video.

ProAir® HFA delivers flexibility, portability, and reduced dosing variability

The ProAir® HFA inhaler is designed to deliver medication for patients on-the-go. The inhaler can be carried and stored in any position without concern over dosing variability.5-7 The ProAir® HFA inhaler doesn’t need to be reprimed if it’s dropped, meaning less medication is used for priming.7

ProAir® HFA delivers long expiration dating for consistent dosing and cost savings8,9

ProAir® HFA has long (24 months) expiration dating, so patients get consistent dosing for up to two years or 200 doses, whichever comes first. Your patients have more time to use all the doses in their inhaler,8,9 which may reduce costs.

References
  1. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm. 1999;186(1):3-12.
  2. Colice GL. New drugs for asthma. Respir Care. 2008;53(6):688-696; discussion 696-698.
  3. Data on file. Teva Respiratory, LLC; 2009.
  4. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104(6):S250-252.
  5. Everard ML, Devadason SG, Summers QA, Le Souëf PN. Factors affecting total and "respirable" dose delivered by a salbutamol metered dose inhaler. Thorax. 1995;50(7):746-749.
  6. Graham SJ, Ormsby ED, Lovering EG. Single spray drug content in a metered dose aerosol formulation and a collection scheme for content uniformity. Pharm Forum. 1992;18(6):4400-4403.
  7. ProAir® HFA Prescribing Information. Teva Respiratory, LLC; 2010.
  8. FDA Letter [January 14, 2008]. Data on file. Teva Respiratory, LLC.
  9. Johns Hopkins Health Alerts. Ask the doctor about your prescriptions. Available at: http://www.johnshopkinshealthalerts.com/alerts/prescription_drugs/JohnsHopkinsPrescriptionDrugsHealthAlert_677-1.html [Accessed May 12, 2010].
ProAir® HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life-threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
  • Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
  • ProAir HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes.
  • Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors, and tricyclic antidepressants.
  • Do not exceed the recommended dose.
  • Adverse events, which occurred at an incidence rate of at least 3% with ProAir HFA, include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis.
©2011 Teva Respiratory, LLC. This site is intended for U.S. residents only. All Rights Reserved.
ProAir® HFA is a registered trademark of Teva Respiratory, LLC.
EIB Active™ is a trademark of Teva Respiratory, LLC. EIB Active™ is sponsored by Teva Respiratory.

101445